相似文献
1
Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?
Circ Heart Fail. 2021 Mar;14(3):e008090. doi: 10.1161/CIRCHEARTFAILURE.120.008090. Epub 2021 Mar 5.
2
Improving Care for Heart Failure With Reduced Ejection Fraction-A Potential Polypill-Based Strategy.
JAMA. 2020 Dec 8;324(22):2259-2260. doi: 10.1001/jama.2020.21395.
3
[Diuretic therapy in acute heart failure].
Med Clin (Barc). 2014 Mar;142 Suppl 1:36-41. doi: 10.1016/S0025-7753(14)70081-8.
4
Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
Clin Res Cardiol. 2020 Aug;109(8):1048-1059. doi: 10.1007/s00392-020-01598-w. Epub 2020 Jan 30.
5
Use of natriuretic-doses of spironolactone for treatment of loop diuretic resistant acute decompensated heart failure.
Int J Cardiol. 2014 Jan 1;170(3):e68-9. doi: 10.1016/j.ijcard.2013.11.023. Epub 2013 Nov 12.
6
Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply.
Mayo Clin Proc. 2021 Feb;96(2):503-506. doi: 10.1016/j.mayocp.2020.11.006.
7
Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
J Am Heart Assoc. 2018 Sep 18;7(18):e009149. doi: 10.1161/JAHA.118.009149.
8
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Circulation. 2020 Nov 3;142(18):1713-1724. doi: 10.1161/CIRCULATIONAHA.120.048739. Epub 2020 Aug 29.
9
Combination of loop diuretics with thiazide-type diuretics in heart failure.
J Am Coll Cardiol. 2010 Nov 2;56(19):1527-34. doi: 10.1016/j.jacc.2010.06.034.
10
Patients with acute heart failure treated with the CARRESS-HF diuretic protocol in association with canrenoate potassium: Tolerance of high doses of canrenoate potassium.
Arch Cardiovasc Dis. 2020 Nov;113(11):679-689. doi: 10.1016/j.acvd.2020.05.017. Epub 2020 Sep 15.
引用本文的文献
1
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.
Am J Cardiovasc Drugs. 2024 May;24(3):343-369. doi: 10.1007/s40256-024-00641-9. Epub 2024 Apr 4.
2
Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.
Heart Fail Rev. 2024 Mar;29(2):305-320. doi: 10.1007/s10741-023-10338-x. Epub 2023 Aug 10.
3
Moving the Paradigm Forward for Prediction and Risk-Based Primary Prevention of Heart Failure in Special Populations.
Curr Atheroscler Rep. 2022 May;24(5):343-356. doi: 10.1007/s11883-022-01009-7. Epub 2022 Mar 2.
4
Frontiers of cardiovascular polypills: From atherosclerosis and beyond.
Trends Cardiovasc Med. 2023 Apr;33(3):182-189. doi: 10.1016/j.tcm.2021.12.013. Epub 2021 Dec 30.
本文引用的文献
1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
2
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
JAMA. 2020 Oct 20;324(15):1522-1531. doi: 10.1001/jama.2020.16641.
3
Polypharmacy in Older Adults Hospitalized for Heart Failure.
Circ Heart Fail. 2020 Nov;13(11):e006977. doi: 10.1161/CIRCHEARTFAILURE.120.006977. Epub 2020 Oct 13.
4
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
5
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5.
6
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Lancet. 2020 Jul 11;396(10244):121-128. doi: 10.1016/S0140-6736(20)30748-0. Epub 2020 May 21.
7
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.
Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29.
8
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
9
Disparities in Cardiovascular Mortality Related to Heart Failure in the United States.
J Am Coll Cardiol. 2019 May 14;73(18):2354-2355. doi: 10.1016/j.jacc.2019.02.042.
10
Clinical Pharmacology in Diuretic Use.
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1248-1257. doi: 10.2215/CJN.09630818. Epub 2019 Apr 1.
Zotero 插件